Prognostic Factors for Survival in
Metastatic Renal Cell Carcinoma:
Retrospective Analysis from
109 Consecutive Patients

Citterio, Giovanni; Bertuzzi, Alexia; Tresoldi, Moreno; Galli, Laura; Lucca, Giuseppe Di; Scaglietti, Ugo; Rugarli, C

doi:10.1159/000474469

Cited by 57 publications

(29 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous report [10] more women tended to have slowgrowing types of tumour than men, but more precise information to support this was not presented. There are reports showing no significant difference in survival between the sexes for patients with metastasis [14,15], but no data on the outcome in recurrent patients were presented. For patients with clear cell carcinoma there are no comparative data currently available.…”

Section: Discussionmentioning

confidence: 99%

Gender as a prognostic factor in patients with renal cell carcinoma

et al. 2002

View full text Add to dashboard Cite

Objective To evaluate gender as a prognostic factor in patients with renal cell carcinoma (RCC), using a retrospective review of patients with RCC stratified according to gender and analysing factors affecting prognosis. Patients and methods From January 1957 to December 1995, 768 patients with pathologically defined RCC (all of whom underwent nephrectomy) were classified as having clear cell carcinoma in 662 (follow-up in 648), papillary RCC in 43 (follow-up in 42), chromophobe cell carcinoma in 36 (follow-up in 34) and cyst-associated RCC in 27 (all followed up) according to the criteria proposed by the World Health Organization. The survival rates were compared between men and women, calculated and stratified according to the subtype of RCC. Results There tended to be a more favourable prognosis in women than in men but the difference was not quite significant (P=0.061). Of those with clear cell carcinoma, women had a more favourable prognosis than men and the difference in survival was significant (P=0.012). No other subtype of RCC was associated with a significant difference in survival between the sexes. There was a smaller proportion of patients with stage IV and a larger proportion with stage I disease in women than in men (P<0.05). Of stage I patients, women had a more favourable prognosis than men (P<0.011). Women had better survival after recurrence than had men, the difference being significant (P=0.007). Conclusion The prognosis is significantly better in women than men with clear cell carcinoma. The factors that contribute to a favourable prognosis in women are the greater proportion of lower stage disease and better survival after recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Gender as a prognostic factor in patients with renal cell carcinoma

et al. 2002

View full text Add to dashboard Cite

show abstract

“…3,10,12,13 Recently, 2 studies indicated that better survival could be expected in young patients and that age was an independent predictor of RCC-SM. 3,5 These 2 studies involved 106 and 4774 patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy

Karakiewicz

Jeldres

Suardi

et al. 2008

CUAJ

View full text Add to dashboard Cite

Objective: Based on combined data for 4880 patients, 2 previous studies reported that advanced age is a predictor of increased renal cell carcinoma-specific mortality (RCC-SM). We explored the effect of age in cubic spline analyses to identify the age groups with the most elevated risk for renal cell carcinoma (RCC). Methods:Our study included 3595 patients from 14 European centres who had partial or radical nephrectomies. We used the Kaplan-Meier method to compile life tables, and we performed Cox regression analyses to assess RCC-SM. Covariates included age at diagnosis, sex, TNM (tumour, node, metastasis) stage, tumour size, Fuhrman grade, symptom classification and histological subtype.

show abstract

“…PS has consistently proven to be a strong prognostic factor. 15,[17][18][19][20] Strict patient selection, including a 46 month life-expectancy, limited the variability in adverse factors, except for anemia (Hb o12 g/dl) and PS (either 0 or 1). The limited number of responses impedes identifying factors predictive of response, especially among this fairly homogenous group.…”

Section: Discussionmentioning

confidence: 99%

“…Poor performance status has uniformly been associated with poor prognosis for advanced RCC. [15][16][17][18][19][20] Blaise et al 14 demonstrated pre-transplant progressive disease as an adverse prognostic factor among 57 solid tumor patients undergoing NST. However, we are not aware of data assessing known RCC prognostic factors to patients undergoing NST.…”

Section: Survival Analysismentioning

confidence: 99%

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

Artz

Besien

Zimmerman

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Nonmyeloablative allogeneic stem cell transplantation (NST) has considerable activity in patients with metastatic renal cell carcinoma (RCC), although there are limited long-term follow-up data. Between February 1999 and May 2003, 18 patients with metastatic RCC underwent 19 matched-sibling NSTs after conditioning with fludarabine and cyclophosphamide with tacrolimus and mycophenolate mofetil as posttransplant immunosuppression. Among the four objective responses, all were partial and have relapsed with a median response duration of 609 days (range, 107-926). All responders are alive at a median of 41 months. Median overall survival for the entire cohort was 14 months. There were four early treatment-related deaths and one late treatment-related death. Eight patients died from progressive disease and five (28%) from treatment-related mortality. Stratifying transplant outcome as early death, intermediate (no response, no early death), or response, the combination of pre-treatment anemia and decreased performance status, was associated with adverse outcome (P ¼ 0.015) and reduced survival (HR 5.4, 95% confidence interval of 1.4 to 21, P ¼ 0.007). Responders demonstrated prolonged survival compared to nonresponders (P ¼ 0.002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification.

show abstract

Prognostic Factors for Survival in Metastatic Renal Cell Carcinoma: Retrospective Analysis from 109 Consecutive Patients

Cited by 57 publications

References 14 publications

Gender as a prognostic factor in patients with renal cell carcinoma

Gender as a prognostic factor in patients with renal cell carcinoma

Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

Contact Info

Product

Resources

About